Study Finds Experimental Vaccine Protects Monkeys From Blinding Trachoma

“An attenuated, or weakened, strain of Chlamydia trachomatis bacteria can be used as a vaccine to prevent or reduce the severity of trachoma, the world’s leading cause of infectious blindness, suggest findings from a National Institutes of Health (NIH) study in monkeys,” an NIH press release reports. The study, published in the Journal of Experimental Medicine on Tuesday, used cynomolgus macaque monkeys in the experiment “because their immune responses closely predict those of humans,” the press release states.  “If this approach demonstrates continued success, the implications could be enormous for the tens of millions of people affected by trachoma, a neglected disease of poverty primarily seen in Asia and sub-Saharan Africa,” said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at NIH, according to the press release (10/10).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.